Copyright © 2014 Bodil Ivarsson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are fatal, noncurable, but treatable diseases that strongly affect the patients.Objective. To describe patients ’ experience of information relating to PAHor CTEPH.Methods. A qualitativemethod using content analysis was applied. Seventeen patients (thirteen women and four men) aged 28–73 years from a regional PAH centre were individually interviewed. Results. Three categories that desc...
Objectives Pulmonary hypertension is a life-shortening disease that has a considerable impact on qua...
Article full text The article associated with this page has been accepted for online publicatio...
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) shar...
Copyright © 2014 Bodil Ivarsson et al. This is an open access article distributed under the Creative...
Background. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension ...
Objective: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (...
As pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) a...
Pulmonary arterial hypertension (PAH) is a rare, debilitating and rapidly progressive disease. Altho...
Purpose: To describe symptoms experienced by pulmonary arterial hyper-tension (PAH) patients and the...
Introduction/objective: Diagnostic delays in pulmonary arterial hypertension (PAH) and chronic throm...
Objectives: Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are se...
Objectives: Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are se...
Abstract Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonar...
Pulmonary arterial hypertension has evolved from a fatal disease with few treatment options to a chr...
Copyright © 2013 Rui Baptista et al. This is an open access article distributed under the Creative C...
Objectives Pulmonary hypertension is a life-shortening disease that has a considerable impact on qua...
Article full text The article associated with this page has been accepted for online publicatio...
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) shar...
Copyright © 2014 Bodil Ivarsson et al. This is an open access article distributed under the Creative...
Background. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension ...
Objective: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (...
As pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) a...
Pulmonary arterial hypertension (PAH) is a rare, debilitating and rapidly progressive disease. Altho...
Purpose: To describe symptoms experienced by pulmonary arterial hyper-tension (PAH) patients and the...
Introduction/objective: Diagnostic delays in pulmonary arterial hypertension (PAH) and chronic throm...
Objectives: Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are se...
Objectives: Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are se...
Abstract Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonar...
Pulmonary arterial hypertension has evolved from a fatal disease with few treatment options to a chr...
Copyright © 2013 Rui Baptista et al. This is an open access article distributed under the Creative C...
Objectives Pulmonary hypertension is a life-shortening disease that has a considerable impact on qua...
Article full text The article associated with this page has been accepted for online publicatio...
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) shar...